ACADIA Pharmaceuticals Inc
(NAS:ACAD)
$
16.95
-0.42 (-2.42%)
Market Cap: 2.89 Bil
Enterprise Value: 2.37 Bil
PE Ratio: 22.27
PB Ratio: 5.01
GF Score: 75/100 ACADIA Pharmaceuticals Inc at Bank of America Healthcare Conference Transcript
May 10, 2022 / 10:20PM GMT
Release Date Price:
$16.84
(+2.81%)
Tazeen Ahmad
BofA Securities, Research Division - MD in Equity Research & Research Analyst
Everybody, good afternoon. So thanks for joining us again at the Bank of America Healthcare Conference. I am Tazeen Ahmad. I am one of the SMID biotech analysts here at the bank. It's a pleasure for us to have our next presenting company with us, ACADIA Pharmaceuticals. Sitting next to me are Steve and Mark. I'll let you guys introduce yourselves, and then maybe, Steve, you can give us a quick overview of the company, and then we can do a little bit more specific Q&A after that, if that works for you.
Stephen R. Davis
ACADIA Pharmaceuticals Inc. - CEO & Director
Yes, it sounds great. So I'm Steve Davis, I'm the CEO of ACADIA.
Mark C. Schneyer
ACADIA Pharmaceuticals Inc. - Executive VP & CFO
And I'm Mark Schneyer, I'm the CFO of ACADIA.
Stephen R. Davis
ACADIA Pharmaceuticals Inc. - CEO & Director
Great. So thanks very much for having us, Tazeen. Thanks to
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot